PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Xiaolu YuYiru LongBinfan ChenYongliang TongMengwen ShanXiaomin JiaChao HuMeng LiuJi ZhouFeng TangHenglei LuRunqiu ChenPan XuWei HuangJin RenYakun WanJianhua SunJia LiGuangyi JinLikun GongPublished in: Journal for immunotherapy of cancer (2022)
The novel PD-L1/TLR7 dual-targeting NDC exhibited potent efficacy against heterogeneous tumors through orchestrating innate and adaptive immunity, which could act as a promising strategy to improve ICB therapy and shows prospects for clinical development.